Sotera Health (SHC) Q3 2026 Earnings Call Transcript

Sotera Health reported Q3 2026 revenue of $325 million, up 4.4%, and adjusted EBITDA of $171 million, up 4.0% at constant currency; adjusted EPS rose 12% year over year to $0.29. The company reaffirmed 2026 revenue guidance of $1.233 billion-$1.25 billion and adjusted EBITDA guidance of $632 million-$641 million, while citing softer European medical-device demand and expecting Sterigenics Q4 revenue to be flat sequentially. Net leverage was 2.9x, within its 2x-3x target range, following a Moody’s credit-rating upgrade.

Analysis

The key risk is not a broad collapse in demand but a shift from volume-led growth to pricing carrying the near-term result. Sterigenics’ pricing contribution currently cushions softer activity; if customers keep delaying procedures or sterilization runs, lower utilization could pressure operating leverage even while reported revenue remains positive. The broad European softness and flat sequential Q4 outlook make 2027 volume trends the central underwriting question—not the cobalt-60 timing volatility, which should not be extrapolated as structural weakness. Nelson Labs’ project-driven EAS strength is also a quality-of-growth caveat: management does not expect a lasting mix shift, and the segment’s margin decline shows that revenue growth alone may not translate cleanly into earnings.

Over 1–3 months, watch for evidence that European softness is spreading to U.S. customers, and whether Q4 delivery holds the guide. Over 6–18 months, lower planned CapEx could improve cash conversion and leverage, but the benefit is unquantified and may compete with M&A or other capital uses. Litigation remains a separate tail risk, with key proceedings extending into 2027. The contrarian positive: stable pricing, customer stickiness, and capacity investments may help SHC absorb a short cyclical pause; the reaffirmed outlook is not proof that demand has bottomed.

Key Decisions for Investors

• Do not chase SHC on the quarter alone. Treat it as a hold/watch rather than a fresh directional entry until Q4 results and 2027 guidance clarify whether Sterigenics volumes stabilize.
• For existing SHC exposure, consider a limited, defined-risk put spread only if post-call option pricing is reasonable; the hedge thesis is further volume deterioration, not Nordion’s harvest timing. Avoid outright shorting without confirming valuation and borrow costs.
• Upgrade the thesis if Sterigenics maintains pricing while volume trends stabilize, and management quantifies a meaningful 2027 CapEx reduction that converts into stronger free cash flow. Falsify the near-term downside case if Q4 meets guidance and U.S. demand remains stable.
• Reassess or reduce exposure if 2027 guidance points to sustained Sterigenics volume deceleration, margin pressure, or if litigation developments materially worsen the expected financial exposure. Verify the relevant court rulings and company disclosures before sizing that risk.